PrenaTest® is now reimbursed in Switzerland by Helsana’s private supplemental insurance PRIMEO
Patients benefit from the partnership between LifeCodexx AG and Helsana with better prices and faster availability of results
Konstanz, Germany – Starting immediately, pregnant women will be reimbursed by Helsana for the costs of the PrenaTest®, Europe’s first non-invasive prenatal test. The Helsana Group is the leading Swiss health and accident insurer and protects 1.9 million insured persons from the financial consequences of illness, accident, pregnancy and old age.
A precondition for cost coverage is conclusion of the private outpatient supplemental insurance PRIMEO. But women with Helsana insurance without PRIMEO also benefit from the new partnership between LifeCodexx AG and Helsana. They also receive the blood test under preferential conditions. The offer is directed at pregnant women over age 35 as well as younger women who have been identified by the physician as having an increased risk of chromosomal changes in their unborn child, as well as pregnant women with psychological stress. Along with a reduced price, it includes a guarantee that the test result will be received within only a few days.
“We are proud to now be a preferred partner of Helsana in the field of diagnostic laboratory testing with a focus on molecular genetic analyses. We are aware of the responsibility of this leading role,” says Dr. Michael Lutz, CEO of LifeCodexx AG. “With this important partnership, we come much closer to our objective of making our high-quality PrenaTest® available to as many affected women in Switzerland as possible.”
“Helsana is very pleased to collaborate with LifeCodexx, a leading company in the field of non-invasive prenatal tests,” says Giancarlo Covino, head of service contracting at Helsana. “Thanks to the partnership with LifeCodexx, PRIMEO insureds receive paid access, in terms of improved medical care, to a non-invasive prenatal test which meets the latest technological and scientific standards but which is not paid for by the compulsory health insurance, and which, for this reason, is now considered to be a diagnostic innovation of PRIMEO. But Helsana customers who do not have supplemental insurance also benefit from favorable rates of the quality test which represents real added value for the customer.”
The PrenaTest® reliably and safely detects chromosomal disorders in the child from maternal blood starting from the end of the ninth week of pregnancy. Because of its high degree of test accuracy, it supplements ultrasound diagnostics in particular and can thus reduce the number of invasive tests in the case of unaffected pregnancies. In comparison to invasive diagnostic procedures, the PraenaTest® does not present a risk of procedure-related miscarriage.
About LifeCodexx AG
Headquartered in Konstanz (Germany), LifeCodexx AG has been developing innovative and clinically validated non-invasive diagnostic tests based on the newest molecular analytical methods since 2010. With the PrenaTest®, Europe’s first non-invasive prenatal test (NIPT) for the determination of the most common chromosomal disorders in unborn children, launched in 2012, LifeCodexx AG has been changing prenatal diagnostics considerably. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices.
About the Helsana Group
The Helsana Group is Switzerland’s leading health and accident insurer. It offers individuals and companies a complete health and prevention service in the event of sickness and accident. With CHF 5.7 billion in earned premiums, the company is one of the leading providers in the Swiss insurance market. The Helsana Group provides basic, supplementary and accident insurance and operates throughout Switzerland, employing more than 3,000 employees. It is not listed on the stock exchange and is organised as a holding. The Helsana Group comprises Helsana, Progrès, Sansan, Avanex and Maxi.ch (www.helsana.ch). The Helsana Group insures nearly 1.9 million people in Switzerland against the financial consequences of illness, accidents, maternity and old age. As part of its corporate business, which is operated exclusively under the Helsana brand, Helsana insures over 50,000 companies and associations (with over 680,000 insured persons) against the economic consequences of the incapacity to work of employees as a result of accident or illness. Services relating to occupational health management complete the package.
PRIMEO is an innovative supplementary insurance that covers outpatient procedures. Patients have an unrestricted choice of doctors, enjoy a high level of comfort and privacy and benefit from attractive supplementary benefits such as check-ups, high-quality implants, innovative diagnosis and treatment forms and much more.